• Eur J Cardiothorac Surg · Jan 2016

    Comparative Study

    Video-assisted mediastinoscopic lymphadenectomy combined with minimally invasive pulmonary resection for left-sided lung cancer: feasibility and clinical impacts on surgical outcomes†.

    • Ho Jin Kim, Yong-Hee Kim, Se Hoon Choi, Kim Hyeong Ryul HR Department of Thoracic and Cardiovascular Surgery, Asan Medic... more al Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Dong Kwan Kim, and Seung-Il Park. less
    • Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
    • Eur J Cardiothorac Surg. 2016 Jan 1; 49 (1): 308-13.

    ObjectivesAlthough video-assisted mediastinoscopic lymphadenectomy (VAMLA) has greatly increased the accuracy of mediastinal staging, its clinical value as a therapeutic tool for complete mediastinal lymph node dissection in the treatment of left-sided lung cancer is not well elucidated.MethodsWe identified the consecutive 649 patients with left-sided lung cancer undergoing minimally invasive pulmonary resection between July 2002 and June 2013. Among them, 225 patients underwent VAMLA combined with pulmonary resection (VAMLA + VATS group), while the remaining 424 patients underwent VATS procedure only (VATS group). Operative outcomes including procedural time, removed lymph nodes and node stations, complications and the final pathological mediastinal staging in the both groups were evaluated and compared.ResultsThere was no significant difference in the baseline profiles between the two groups. The patients in the VATS + VAMLA group showed significantly shorter operative time (116.8 ± 39.8 vs 159.8 ± 44 .0 min; P < 0.001), more extensive lymph node dissection (total number of removed lymph nodes, 29.7 ± 10.8 vs 23.0 ± 8.6; P < 0.001) and the higher rates of patients with mediastinal lymph nodes removed: Station 2 on the right (12.4 vs 0.2%), Station 2 on the left (15.1 vs 0.2%), Station 4 on the right (42.7 vs 0.9%), Station 4 on the left (87.6 vs 57.3%) and Station 7 (100 vs 99.3%), while maintaining comparable surgical morbidities compared with the VATS group. Also, the patients in the VATS + VAMLA group tended to have higher rates of being upstaged with mediastinal involvement (8.0 vs 5.7%; P = 0.31).ConclusionsVAMLA is a clinically feasible procedure safely performed as a therapeutic tool for complete mediastinal lymph node dissection (MLND), and can be a good complement to minimally invasive pulmonary resection in left-sided lung cancer, where optimal MLND is not always feasible with VATS approach. Further studies are required to investigate the long-term clinical impacts of VAMLA with regard to survival and tumour recurrence.© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

      Pubmed     Full text   Copy Citation  

      Add institutional full text...

    Notes

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.